Huntington's Disease: Current and Future Therapeutic Prospects

被引：27

作者：

Kieburtz, Karl ^{[1
,2
]}

Reilmann, Ralf ^{[3
]}

Olanow, C. Warren ^{[2
,4
]}

机构：

[1] Univ Rochester, Rochester, NY 14627 USA

[2] Clintrex LLC, Sarasota, FL USA

[3] George Huntington Inst, Munster, Germany

[4] Mt Sinai Sch Med, New York, NY USA

来源：

MOVEMENT DISORDERS | 2018年 / 33卷 / 07期

关键词：

Huntington's Disease; Therapy; PLACEBO-CONTROLLED TRIAL; YAC128 MOUSE MODEL; DOUBLE-BLIND; MUTANT HUNTINGTIN; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; MINIPIG MODEL; CELL MODELS; INHIBITOR; PREMANIFEST;

D O I：

10.1002/mds.27363

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable progression. Currently approved therapies are primarily aimed at treating chorea, but do not address the more clinically meaningful motor, behavioral, and cognitive features of the disease. However, there are a number of promising new therapies that are currently being studied in the laboratory, and in the clinic. This article will review the wide variety of therapies currently being tested, the advances in clinical trials and end points, and the many potentially relevant new targets. (C) 2018 International Parkinson and Movement Disorder Society

引用

页码：1033 / 1041

页数：9

共 92 条

[71] Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives [J].

Schapira, Anthony H. V. ;

Olanow, C. Warren ;

Greenamyre, J. Timothy ;

Bezard, Erwan .

LANCET, 2014, 384 (9942) :545-555

[72] Motor, cognitive, and functional declines contribute to a single progressive factor in early HD [J].

Schobel, Scott A. ;

Palermo, Giuseppe ;

Auinger, Peggy ;

Long, Jeffrey D. ;

Ma, Shiyang ;

Khwaja, Omar S. ;

Trundell, Dylan ;

Cudkowicz, Merit ;

Hersch, Steven ;

Sampaio, Cristina ;

Dorsey, E. Ray ;

Leavitt, Blair R. ;

Kieburtz, Karl D. ;

Sevigny, Jeffrey J. ;

Langbehn, Douglas R. ;

Tabrizi, Sarah J. .

NEUROLOGY, 2017, 89 (24) :2495-2502

[73] Behavioral phenotyping of minipigs transgenic for the Huntington gene [J].

Schramke, Sarah ;

Schuldenzucker, Verena ;

Schubert, Robin ;

Frank, Frauke ;

Wirsig, Maike ;

Ott, Stefanie ;

Motlik, Jan ;

Fels, Michaela ;

Kemper, Nicole ;

Hoelzner, Eva ;

Reilmann, Ralf .

JOURNAL OF NEUROSCIENCE METHODS, 2016, 265 :34-45

[74] Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments [J].

Schubert, Robin ;

Frank, Frauke ;

Nagelmann, Nina ;

Liebsch, Lennart ;

Schuldenzucker, Verena ;

Schramke, Sarah ;

Wirsig, Maike ;

Johnson, Hans ;

Kim, Eun Young ;

Ott, Stefanie ;

Hoelzner, Eva ;

Demokritov, Sergej O. ;

Motlik, Jan ;

Faber, Cornelius ;

Reilmann, Ralf .

JOURNAL OF NEUROSCIENCE METHODS, 2016, 265 :46-55

[75] A Futility Study of Minocycline in Huntington's Disease [J].

Schwarz, Heidi ;

Hickey, Charlyne ;

Zimmerman, Carol ;

Mazzoni, Pietro ;

Moskowitz, Carol ;

Rosas, Diana ;

McCall, Marcia ;

Sanchez-Ramos, Juan ;

Perlmutter, Joel ;

Wernle, Angie ;

Higgins, Donald ;

Nickerson, Constance ;

Evans, Sharon ;

Kumar, Rajeev ;

Miracle, Dawn ;

Dure, Leon ;

Pendley, Donna ;

Anderson, Karen ;

Cines, Michelle ;

Ashizawa, Tetsuo ;

Stanton, Penny ;

Fernandez, Hubert ;

Suelter, Michele ;

Leavitt, Blair ;

Decolongon, Joji .

MOVEMENT DISORDERS, 2010, 25 (13) :2219-2224

[76] HUNTINGTON DISEASE - CLINICAL CARE AND EVALUATION [J].

SHOULSON, I ;

FAHN, S .

NEUROLOGY, 1979, 29 (01) :1-3

[77] A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease [J].

Smith, Marianne R. ;

Syed, Adeela ;

Lukacsovich, Tamas ;

Purcell, Judy ;

Barbaro, Brett A. ;

Worthge, Shane A. ;

Wei, Stephen R. ;

Pollio, Giuseppe ;

Magnoni, Letizia ;

Scali, Carla ;

Massai, Luisa ;

Franceschini, Davide ;

Camarri, Michela ;

Gianfriddo, Marco ;

Diodato, Enrica ;

Thomas, Russell ;

Gokce, Ozgun ;

Tabrizi, S. J. ;

Caricasole, Andrea ;

Landwehrmeyer, Bernard ;

Menalled, Liliana ;

Murphy, Carol ;

Ramboz, Sylvie ;

Luthi-Carter, Ruth ;

Westerberg, Goran ;

Marsh, J. Lawrence .

HUMAN MOLECULAR GENETICS, 2014, 23 (11) :2995-3007

[78] Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression [J].

Southwell, Amber L. ;

Smith, Stephen E. P. ;

Davis, Tessa R. ;

Caron, Nicholas S. ;

Villanueva, Erika B. ;

Xie, Yuanyun ;

Collins, Jennifer A. ;

Ye, Min Li ;

Sturrock, Aaron ;

Leavitt, Blair R. ;

Schrum, Adam G. ;

Hayden, Michael R. .

SCIENTIFIC REPORTS, 2015, 5

[79] Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease [J].

Southwell, Amber L. ;

Franciosi, Sonia ;

Villanueva, Erika B. ;

Xie, Yuanyun ;

Winter, Laurie A. ;

Veeraraghavan, Janaki ;

Jonason, Alan ;

Felczak, Boguslaw ;

Zhang, Weining ;

Kovalik, Vlad ;

Waltl, Sabine ;

Hall, George ;

Pouladi, Mahmoud A. ;

Smith, Ernest S. ;

Bowers, William J. ;

Zauderer, Maurice ;

Hayden, Michael R. .

NEUROBIOLOGY OF DISEASE, 2015, 76 :46-56

[80] Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease [J].

Stanek, Lisa M. ;

Yang, Wendy ;

Angus, Stuart ;

Sardi, Pablo S. ;

Hayden, Michael R. ;

Hung, Gene H. ;

Bennett, C. Frank ;

Cheng, Seng H. ;

Shihabuddin, Lamya S. .

JOURNAL OF HUNTINGTONS DISEASE, 2013, 2 (02) :217-228

← 1 2 3 4 5 6 7 8 9 10 →